Tesamorelin is a growth-hormone-releasing factor analogue. Its approved indication is narrow and specific: reduction of excess abdominal fat in adult patients with HIV who have lipodystrophy. That is the population studied and the population the labeling covers.
Labeling is also clear that it has not been shown to improve cardiovascular outcomes or metabolic parameters more broadly, and that continued treatment is required to maintain the effect on visceral fat. Marketing that presents it as a general body-composition or longevity therapy is going well beyond what has been demonstrated.
There are also real safety considerations, including effects on glucose tolerance, injection-site reactions, and cautions relating to malignancy. Those matter to any discussion of use outside the approved population.
Risks and limitations
- Approved only for HIV-associated lipodystrophy in adults, not for general fat loss or aging.
- Effects are not maintained after treatment stops.
- May affect glucose tolerance; requires monitoring.
- Cautions relating to active malignancy are described in labeling.
- Use outside the approved indication is off-label and should be identified as such.